Avenzoar – Committed to the fight against cancer

Avenzoar
Pharmaceuticals

Committed to the fight against cancer

Innovating Oncology Treatments

Avenzoar Pharmaceuticals is a pioneering start-up specialized in developing innovative small molecule therapeutics targeting mechanisms of metastasis and drug resistance.

Our focus is on creating novel therapies that address unmet medical needs in cancer treatment. Founded in 2016, we have a dedicated mission to bring new hope to patients through groundbreaking cancer treatments.

Our Mission

Through cutting-edge research and development, advance the science of oncology and improve patient outcomes with a primary focus on treating recalcitrant cancers, including pancreatic and ovarian cancer, by inhibiting metastasis and chemo-resistance mechanisms.

AP-001

A Promising New Therapy

Our leading investigational drug represents a significant advancement in the treatment of cancer. AP-001 has shown promising results in preclinical studies and is expected to undergo rigorous clinical trials to demonstrate its efficacy and safety in pancreatic cancer patients beginning in 2025.

Dr. Stephen Pandol
Director of Basic and Translational
Pancreas Research at Cedars-Sinai Medical Center

This website ensures that all critical information is easily accessible and clearly communicated to regulatory bodies and potential partners, highlighting Avenzoar Pharmaceuticals’ commitment to advancing oncology treatments and collaborating with industry leaders.

Avenzoar Pharmaceuticals, Inc.

1819 Outpost Drive, Los Angeles,, CA 90068

phone 858.736.7354 | email tbruggeman@avenzoarpharma.com

1819 Outpost Drive, Los Angeles, CA 90068
phone 858.736.7356
email tbruggeman@avenzoarpharma.com